ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 101

Trends In Prescription Of Opioids From 2003-2009 In Persons With Knee Osteoarthritis

Elizabeth Wright1, Jeffrey N. Katz2, Stanley Abrams3, Daniel H. Solomon4 and Elena Losina5, 1Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 3Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 4Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 5Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: opioids, Osteoarthritis, pain management, treatment and utilization review

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) of the knee is a painful condition affecting ~13% of persons >65 years of age. OA is often accompanied by comorbidities. Effective pain control is important for managing this chronic disease. In the last decade, physicians have become increasingly aware of contraindications to NSAIDs due to comorbid conditions. We sought to examine whether physicians have begun to use opioids more frequently.

Methods:  We assembled national cohorts of individuals with knee OA using data from waves of the Medicare Beneficiary Survey (MCBS) administered in the years 2003, 2006, and 2009. We examined temporal trends in opioid prescriptions in these cohorts over time. The MCBS survey consists of a nationally representative sample of Medicare beneficiaries. The MCBS survey data can be linked to Medicare claims. Survey respondents provided data on demographics, health status and prescribed medications. We selected knee OA cohorts from each of the three years from community-dwelling MCBS respondents aged 65 and older who had at least one outpatient visit in Medicare Parts A or B with an ICD-9-CM diagnostic code of a) 715.x6 (OA of knee) or b) ICD-9 code of 719.46 (knee pain) plus 715.x8, 715.x9 or 715.x0 (OA at other specified sites, at multiple sites and at unspecified sites, respectively). Functional status was categorized as poor if the survey respondent indicated “a lot of difficulty” or “inability” to walk ¼ mile or 2-3 blocks. The following six comorbidity categories were assigned from Medicare Parts A or B claims: cancer, cardiovascular disease, musculoskeletal disease other than OA, diabetes, depression and chronic obstructive pulmonary disease (COPD). We included all prescribed medication records classified as opioids under the MCBS antiarthritic or analgesic categories. The outcome was defined as receiving at least one prescription for an opioid in the year of study. We used multivariate logistic regression to establish whether opioid use changed over time and identify factors leading to greater utilization of opioids in elderly persons with OA.

Results: 488 (5%) subjects from the 2003 MCBS survey, 477 (5%) from the 2006 MCBS and 422 (5%) from the 2009 MCBS were identified with knee OA. Mean age and sex were similar across years (77 years, 70% females). We found a significant increase in opioid prescribing between 2003 and 2009, with 31% of the patients receiving opioids in 2003, 39% in 2006 and 40% in 2009 (OR 1.5, 95% CI 1.1, 2.0 for both years 2006 and 2009 compared to  2003). Across all time periods, independent correlates of opioids use included: female sex (OR 1.5, 95% CI 1.2, 2.0), functional limitations (OR 2.1, 95% CI 1.7, 2.7), poor self-reported health status (OR 1.6, 95% CI 1.2, 2.0), COPD (OR 1.4, 95% CI 1.0, 1.8) and musculoskeletal disease in addition to OA (OR 1.9, 95% CI 1.2, 2.8).   

Conclusion: Opioid use in elderly persons with knee OA increased substantially between 2003 and 2009. The more frequent use of opioids is likely due to low efficacy and to toxicity of other classes of analgesics drugs currently used for pain relief in knee OA patients. As prevalence and incidence of knee OA continues to grow the public health impact of greater use of opioids should be monitored carefully.


Disclosure:

E. Wright,
None;

J. N. Katz,

OARSI,

6,

JBJS,

9;

S. Abrams,
None;

D. H. Solomon,

Lilly, Amgen, CORRONA,

2,

Lilly, Novartis, BMS, Pfizer,

6,

Lilly, BMS, Novartis,

9;

E. Losina,

JBJS,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-prescription-of-opioids-from-2003-2009-in-persons-with-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology